• Medivir’s randomized Phase 2 FLEX-HCC trial remains underway, with patient recruitment progressing as planned at 12 South Korean hospitals.
• The study compares fostrox with lenvatinib against lenvatinib alone as second-line treatment for advanced liver cancer following immunotherapy.
• Preparations are progressing for MIV-711 proof-of-concept studies in osteogenesis imperfecta and Perthes disease; the latter requires a pediatric oral formulation.
• SEK 336 million raised since December 2025 provides funding for all three Phase 2 studies, supporting operations until at least 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medivir AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.